Final 10-year analysis of the phase 3 RELEVANCE RCT in 1030 patients with untreated follicular lymphoma: lenalidomide plus rituximab vs rituximab-chemotherapy gave comparable median PFS (110.6 vs 102.8 months); 10-year OS 82.4% vs 81.1%.
RCTn = 1,030
Gower et al. Lenalidomide plus rituximab for previously untreated advanced follicular lymphoma: the 10-year RELEVANCE trial analysis